Normothermic Machine Perfusion Market

According to Coherent Market Insights, the Global Normothermic Machine Perfusion Market is estimated to be valued at USD 2.05 Bn in 2026 and is expected to reach USD 6.57 Bn by 2033, expanding at a compound annual growth rate (CAGR) of 18.11% from 2026 to 2033. The global normothermic machine perfusion market represents a transformative advancement in organ preservation technology, fundamentally revolutionizing transplantation medicine by maintaining organs at physiological temperatures during storage and transport. Unlike traditional cold storage methods, normothermic machine perfusion systems preserve organs at body temperature (37°C) while providing continuous oxygenated blood flow, significantly extending organ viability and improving transplantation outcomes. This innovative technology addresses critical challenges in organ transplantation, including organ shortage, preservation quality, and extended storage times, thereby expanding the donor pool and enhancing recipient survival rates.

The market encompasses sophisticated perfusion devices, specialized perfusion solutions, monitoring systems, and comprehensive service networks that support healthcare institutions worldwide. As healthcare systems globally face increasing demand for organ transplants amid growing prevalence of end-stage organ diseases, normothermic machine perfusion technology emerges as a crucial solution bridging the gap between organ availability and patient needs. The technology's proven ability to assess organ functionality before transplantation, reduce ischemia-reperfusion injury, and enable ex-vivo organ repair positions it as an indispensable component of modern transplantation protocols, driving substantial market growth and attracting significant investment from medical device manufacturers and healthcare providers.

Market Dynamics

The global normothermic machine perfusion market experiences robust growth driven by multiple compelling factors, with the primary driver being the critical shortage of transplantable organs worldwide, creating urgent demand for technologies that maximize organ utilization and extend preservation periods. Increasing prevalence of chronic diseases such as liver cirrhosis, kidney failure, and heart disease significantly amplifies the patient population requiring organ transplants, while aging demographics globally contribute to both increased organ demand and expanded donor criteria acceptance. Technological advancements in perfusion systems, including automated monitoring, real-time organ assessment capabilities, and improved biocompatibility of perfusion solutions, enhance clinical outcomes and drive adoption among transplant centers.

Growing clinical evidence demonstrating superior organ preservation, reduced primary non-function rates, and improved long-term graft survival compared to cold storage methods strengthens physician confidence and institutional adoption.

However, market restraints include substantial capital investment requirements for perfusion equipment, ongoing operational costs including specialized perfusion fluids and technical expertise, and complex regulatory pathways for device approval across different regions. Limited reimbursement coverage in certain healthcare systems creates financial barriers for widespread adoption, while the need for specialized training and technical support infrastructure poses implementation challenges for smaller transplant centers. Despite these constraints, significant opportunities emerge from expanding applications beyond liver and kidney preservation to include heart, lung, and pancreas perfusion, growing acceptance of extended criteria donor organs through improved preservation techniques, and increasing healthcare infrastructure development in emerging markets where transplantation programs are expanding rapidly.

Key Features of the Study

• This report provides in-depth analysis of the global normothermic machine perfusion market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global normothermic machine perfusion market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include TransMedics Group Inc, Organ Recovery Systems, XVIVO Perfusion AB, OrganOx Limited, Getinge (Paragonix Technologies), Bridge to Life Ltd, Waters Medical Systems, Preservation Solutions Inc, Institut Georges Lopez SA, EBERS Medical Technology SL, Shenzhen Lifotronic Technology Co Ltd, Genus Medical Technologies LLC, Terumo Corporation, Medtronic plc, and LivaNova Plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global normothermic machine perfusion market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global normothermic machine perfusion market

Market Segmentation

• Application Insights (Revenue, USD Bn, 2021 - 2033)
• Organ Preservation
• Organ Reconditioning
• Organ Transplantation
• Organ Type Insights (Revenue, USD Bn, 2021 - 2033)
• Kidney
• Liver
• Heart
• Lung
• Pancreas
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals and Surgical Centers
• Organ Transplantation Centers
• Research Laboratories
• Organ Procurement Organizations
• Type of Perfusion Insights (Revenue, USD Bn, 2021 - 2033)
• Hypothermic Machine Perfusion
• Normothermic Machine Perfusion
• Component Insights (Revenue, USD Bn, 2021 - 2033)
• Consumables (Tubing, Solution Kits, Filters)
• Devices (Perfusion Machines, Sensors)
• Software (Monitoring and Data Analysis Systems)
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• TransMedics Group Inc
• Organ Recovery Systems
• XVIVO Perfusion AB
• OrganOx Limited
• Getinge (Paragonix Technologies)
• Bridge to Life Ltd
• Waters Medical Systems
• Preservation Solutions Inc
• Institut Georges Lopez SA
• EBERS Medical Technology SL
• Shenzhen Lifotronic Technology Co Ltd
• Genus Medical Technologies LLC
• Terumo Corporation
• Medtronic plc
• LivaNova Plc

Show more